KMT2D and prostate carcinoma: In acute myeloid leukemia, follicular lymphoma and DLBCL, KMT2D could inhibit tumorigenesis and metastasis [43, 44], but in solid cancer, such as prostate cancer, KMT2D is critical factor for promoting tumor cell proliferation [45].